Genome-wide and gene-specific epigenomic platforms for hepatocellular carcinoma biomarker development trials

Christina Michailidi, Ethan Soudry, Mariana Brait Rodrigues De Oliveira, Leonel Maldonado, Andrew Jaffe, Carmen Ili-Gangas, Priscilla Brebi-Mieville, Jimena Perez, Myoung Sook Kim, Xiaoli Zhong, Quiang Yang, Blanca Valle, Stephen Meltzer, Michael Torbenson, Manel Esteller, David Sidransky, Rafael Guerrero-Preston

Research output: Contribution to journalArticle

Abstract

The majority of the epigenomic reports in hepatocellular carcinoma have focused on identifying novel differentially methylated drivers or passengers of the oncogenic process. Few reports have considered the technologies in place for clinical translation of newly identified biomarkers. The aim of this study was to identify epigenomic technologies that need only a small number of samples to discriminate HCC from non-HCC tissue, a basic requirement for biomarker development trials. To assess that potential, we used quantitative Methylation Specific PCR, oligonucleotide tiling arrays, and Methylation BeadChip assays. Concurrent global DNA hypomethylation, gene-specific hypermethylation, and chromatin alterations were observed as a hallmark of HCC. A global loss of promoter methylation was observed in HCC with the Illumina BeadChip assays and the Nimblegen oligonucleotide arrays. HCC samples had lower median methylation peak scores and a reduced number of significant promoter-wide methylated probes. Promoter hypermethylation of RASSF1A, SSBP2, and B4GALT1 quantified by qMSP had a sensitivity ranging from 38% to 52%, a specificity of 100%, and an AUC from 0.58 to 0.75. A panel combining these genes with HCC risk factors had a sensitivity of 87%, a specificity of 100%, and an AUC of 0.91.

Original languageEnglish (US)
Article number597164
JournalGastroenterology Research and Practice
Volume2014
DOIs
StatePublished - 2014

Fingerprint

Epigenomics
Methylation
Hepatocellular Carcinoma
Biomarkers
Genome
Oligonucleotide Array Sequence Analysis
Genes
Area Under Curve
Technology
Chromatin
Polymerase Chain Reaction
DNA

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Genome-wide and gene-specific epigenomic platforms for hepatocellular carcinoma biomarker development trials. / Michailidi, Christina; Soudry, Ethan; Brait Rodrigues De Oliveira, Mariana; Maldonado, Leonel; Jaffe, Andrew; Ili-Gangas, Carmen; Brebi-Mieville, Priscilla; Perez, Jimena; Kim, Myoung Sook; Zhong, Xiaoli; Yang, Quiang; Valle, Blanca; Meltzer, Stephen; Torbenson, Michael; Esteller, Manel; Sidransky, David; Guerrero-Preston, Rafael.

In: Gastroenterology Research and Practice, Vol. 2014, 597164, 2014.

Research output: Contribution to journalArticle

Michailidi, C, Soudry, E, Brait Rodrigues De Oliveira, M, Maldonado, L, Jaffe, A, Ili-Gangas, C, Brebi-Mieville, P, Perez, J, Kim, MS, Zhong, X, Yang, Q, Valle, B, Meltzer, S, Torbenson, M, Esteller, M, Sidransky, D & Guerrero-Preston, R 2014, 'Genome-wide and gene-specific epigenomic platforms for hepatocellular carcinoma biomarker development trials', Gastroenterology Research and Practice, vol. 2014, 597164. https://doi.org/10.1155/2014/597164
Michailidi, Christina ; Soudry, Ethan ; Brait Rodrigues De Oliveira, Mariana ; Maldonado, Leonel ; Jaffe, Andrew ; Ili-Gangas, Carmen ; Brebi-Mieville, Priscilla ; Perez, Jimena ; Kim, Myoung Sook ; Zhong, Xiaoli ; Yang, Quiang ; Valle, Blanca ; Meltzer, Stephen ; Torbenson, Michael ; Esteller, Manel ; Sidransky, David ; Guerrero-Preston, Rafael. / Genome-wide and gene-specific epigenomic platforms for hepatocellular carcinoma biomarker development trials. In: Gastroenterology Research and Practice. 2014 ; Vol. 2014.
@article{1ee5e31b9f2d4974a37c43165f4573dd,
title = "Genome-wide and gene-specific epigenomic platforms for hepatocellular carcinoma biomarker development trials",
abstract = "The majority of the epigenomic reports in hepatocellular carcinoma have focused on identifying novel differentially methylated drivers or passengers of the oncogenic process. Few reports have considered the technologies in place for clinical translation of newly identified biomarkers. The aim of this study was to identify epigenomic technologies that need only a small number of samples to discriminate HCC from non-HCC tissue, a basic requirement for biomarker development trials. To assess that potential, we used quantitative Methylation Specific PCR, oligonucleotide tiling arrays, and Methylation BeadChip assays. Concurrent global DNA hypomethylation, gene-specific hypermethylation, and chromatin alterations were observed as a hallmark of HCC. A global loss of promoter methylation was observed in HCC with the Illumina BeadChip assays and the Nimblegen oligonucleotide arrays. HCC samples had lower median methylation peak scores and a reduced number of significant promoter-wide methylated probes. Promoter hypermethylation of RASSF1A, SSBP2, and B4GALT1 quantified by qMSP had a sensitivity ranging from 38{\%} to 52{\%}, a specificity of 100{\%}, and an AUC from 0.58 to 0.75. A panel combining these genes with HCC risk factors had a sensitivity of 87{\%}, a specificity of 100{\%}, and an AUC of 0.91.",
author = "Christina Michailidi and Ethan Soudry and {Brait Rodrigues De Oliveira}, Mariana and Leonel Maldonado and Andrew Jaffe and Carmen Ili-Gangas and Priscilla Brebi-Mieville and Jimena Perez and Kim, {Myoung Sook} and Xiaoli Zhong and Quiang Yang and Blanca Valle and Stephen Meltzer and Michael Torbenson and Manel Esteller and David Sidransky and Rafael Guerrero-Preston",
year = "2014",
doi = "10.1155/2014/597164",
language = "English (US)",
volume = "2014",
journal = "Gastroenterology Research and Practice",
issn = "1687-6121",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Genome-wide and gene-specific epigenomic platforms for hepatocellular carcinoma biomarker development trials

AU - Michailidi, Christina

AU - Soudry, Ethan

AU - Brait Rodrigues De Oliveira, Mariana

AU - Maldonado, Leonel

AU - Jaffe, Andrew

AU - Ili-Gangas, Carmen

AU - Brebi-Mieville, Priscilla

AU - Perez, Jimena

AU - Kim, Myoung Sook

AU - Zhong, Xiaoli

AU - Yang, Quiang

AU - Valle, Blanca

AU - Meltzer, Stephen

AU - Torbenson, Michael

AU - Esteller, Manel

AU - Sidransky, David

AU - Guerrero-Preston, Rafael

PY - 2014

Y1 - 2014

N2 - The majority of the epigenomic reports in hepatocellular carcinoma have focused on identifying novel differentially methylated drivers or passengers of the oncogenic process. Few reports have considered the technologies in place for clinical translation of newly identified biomarkers. The aim of this study was to identify epigenomic technologies that need only a small number of samples to discriminate HCC from non-HCC tissue, a basic requirement for biomarker development trials. To assess that potential, we used quantitative Methylation Specific PCR, oligonucleotide tiling arrays, and Methylation BeadChip assays. Concurrent global DNA hypomethylation, gene-specific hypermethylation, and chromatin alterations were observed as a hallmark of HCC. A global loss of promoter methylation was observed in HCC with the Illumina BeadChip assays and the Nimblegen oligonucleotide arrays. HCC samples had lower median methylation peak scores and a reduced number of significant promoter-wide methylated probes. Promoter hypermethylation of RASSF1A, SSBP2, and B4GALT1 quantified by qMSP had a sensitivity ranging from 38% to 52%, a specificity of 100%, and an AUC from 0.58 to 0.75. A panel combining these genes with HCC risk factors had a sensitivity of 87%, a specificity of 100%, and an AUC of 0.91.

AB - The majority of the epigenomic reports in hepatocellular carcinoma have focused on identifying novel differentially methylated drivers or passengers of the oncogenic process. Few reports have considered the technologies in place for clinical translation of newly identified biomarkers. The aim of this study was to identify epigenomic technologies that need only a small number of samples to discriminate HCC from non-HCC tissue, a basic requirement for biomarker development trials. To assess that potential, we used quantitative Methylation Specific PCR, oligonucleotide tiling arrays, and Methylation BeadChip assays. Concurrent global DNA hypomethylation, gene-specific hypermethylation, and chromatin alterations were observed as a hallmark of HCC. A global loss of promoter methylation was observed in HCC with the Illumina BeadChip assays and the Nimblegen oligonucleotide arrays. HCC samples had lower median methylation peak scores and a reduced number of significant promoter-wide methylated probes. Promoter hypermethylation of RASSF1A, SSBP2, and B4GALT1 quantified by qMSP had a sensitivity ranging from 38% to 52%, a specificity of 100%, and an AUC from 0.58 to 0.75. A panel combining these genes with HCC risk factors had a sensitivity of 87%, a specificity of 100%, and an AUC of 0.91.

UR - http://www.scopus.com/inward/record.url?scp=84900334323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900334323&partnerID=8YFLogxK

U2 - 10.1155/2014/597164

DO - 10.1155/2014/597164

M3 - Article

C2 - 24829571

AN - SCOPUS:84900334323

VL - 2014

JO - Gastroenterology Research and Practice

JF - Gastroenterology Research and Practice

SN - 1687-6121

M1 - 597164

ER -